Calcific Degeneration of CorMatrix 4 Years After Bicuspidization of Unicuspid Aortic Valve

Nezhad, Zahra Mosala; Baldin, Paméla; Poncelet, Alain; Khoury, Gébrine El

doi:10.1016/j.athoracsur.2017.07.040

Cited by 22 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the literature describing AVrs using CorMatrix do not indicate good outcomes, irrespective of follow‐up time. Hoffman and associates reported significant valve insufficiency in five (83%) pediatric patients at 4 months to a 1‐year follow‐up, Mosala and associates demonstrated similar bad outcomes at 4‐year follow‐up for a pediatric patient requiring a reoperation for valve failure, severe calcification, fibrosis, and retraction 15,16 . Furthermore, the studies comparing CorMatrix and autologous pericardium also reported no significant advantages for CorMatrix from histological, echocardiogram, and clinical data.…”

Section: Discussionmentioning

confidence: 97%

Pediatric aortic valve repair: Any development in the material for cusp extension valvuloplasty?

Siddiqi

Lee

et al. 2021

Journal of Cardiac Surgery

View full text Add to dashboard Cite

Background Aortic cusp extension is a technique for aortic valve (AV) repairs in pediatric patients. The choice of the material used in this procedure may influence the time before reoperation is required. We aimed to assess postoperative and long‐term outcomes of patients receiving either pericardial or synthetic repairs. Methods We conducted a single‐center, retrospective study of pediatric patients undergoing aortic cusp extension valvuloplasty (N = 38) with either autologous pericardium (n = 30) or CorMatrix (n = 8) between April 2009 and July 2016. Short‐ and long‐term postoperative outcomes were compared between the two groups. Freedom from reoperation was compared using Kaplan–Meier analysis. Degree of aortic stenosis (AS) and aortic regurgitation (AR) were recorded at baseline, postoperatively, and at outpatient follow‐up. Results At 5 years after repair, freedom from reoperation was significantly lower in the CorMatrix group (12.5%) compared to the pericardium group (62.5%) (p = .01). For the entire cohort, there was a statistically significant decrease in the peak trans‐valvar gradient between preoperative and postoperative assessments with no significant change at outpatient follow‐up. In the pericardium group, 28 (93%) had moderate to severe AR at baseline which improved to 11 (37%) postoperatively and increased to 21 (70%) at time of follow‐up. In the biomaterial group, eight (100%) had moderate to severe AR which improved to three (38%) postoperatively and increased to seven (88%) at time of follow‐up. Conclusion In terms of durability, the traditional autologous pericardium may outperform the new CorMatrix for AV repairs using the cusp extension method.

show abstract

Section: Discussionmentioning

confidence: 97%

Pediatric aortic valve repair: Any development in the material for cusp extension valvuloplasty?

Siddiqi

Lee

et al. 2021

Journal of Cardiac Surgery

View full text Add to dashboard Cite

show abstract

“…13,14 Overall, long-term studies using CorMatrix are sparse, but multiple midterm studies and case reports demonstrate poor durability of the scaffold for valvular repair due to progressive inflammation and fibrotic degeneration. 15,16 However, despite multiple studies now cautioning against the use of CorMatrix for long-term repair and the need for reoperation, total resorption of the patch is seemingly rare.…”

Section: Discussionmentioning

confidence: 99%

Recurrent ventricular septal defect following closure CorMatrix: A case report

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 71 , 72 An inflammatory response comprised of eosinophils, macrophages, and giant cell reactions has been repeatedly demonstrated in explants of CorMatrix and CardioCel. 76 , 80 , 87 In limited observation of a single patient with 2 CorMatrix patches, 1 patch generated a marked inflammatory response while the other did not, indicating that such responses could be tissue specific or related to the surgical procedure. 86 In many but not all cases, explanted xenografts showing inflammation also show fibrosis and calcification, processes that are undesirable for development of true functional neotissues.…”

Section: Allogeneic and Xenogeneic Materialsmentioning

confidence: 99%

Bioengineering Human Tissues and the Future of Vascular Replacement

Naegeli

Kural

et al. 2022

Circulation Research

View full text Add to dashboard Cite

Cardiovascular defects, injuries, and degenerative diseases often require surgical intervention and the use of implantable replacement material and conduits. Traditional vascular grafts made of synthetic polymers, animal and cadaveric tissues, or autologous vasculature have been utilized for almost a century with well-characterized outcomes, leaving areas of unmet need for the patients in terms of durability and long-term patency, susceptibility to infection, immunogenicity associated with the risk of rejection, and inflammation and mechanical failure. Research to address these limitations is exploring avenues as diverse as gene therapy, cell therapy, cell reprogramming, and bioengineering of human tissue and replacement organs. Tissue-engineered vascular conduits, either with viable autologous cells or decellularized, are the forefront of technology in cardiovascular reconstruction and offer many benefits over traditional graft materials, particularly in the potential for the implanted material to be adopted and remodeled into host tissue and thus offer safer, more durable performance. This review discusses the key advances and future directions in the field of surgical vascular repair, replacement, and reconstruction, with a focus on the challenges and expected benefits of bioengineering human tissues and blood vessels.

show abstract

Calcific Degeneration of CorMatrix 4 Years After Bicuspidization of Unicuspid Aortic Valve

Cited by 22 publications

References 6 publications

Pediatric aortic valve repair: Any development in the material for cusp extension valvuloplasty?

Pediatric aortic valve repair: Any development in the material for cusp extension valvuloplasty?

Recurrent ventricular septal defect following closure CorMatrix: A case report

Bioengineering Human Tissues and the Future of Vascular Replacement

Contact Info

Product

Resources

About